London
United Kingdom
Research Article
Magnetic Mirtazapine Loaded Poly(propylene glycol)bis(2aminopropylether) (PPG-NH2, MW_2000) Nanocarriers for Controlled Drug Release
Author(s): Jibowu T and Rohani SJibowu T and Rohani S
Mirtazapine is an antidepressant that was introduced in 1996 for the treatment of moderate and severe depression. Mirtazapine is the only tetracyclic antidepressant that is approved by the Food and Drug Administration to treat depression. Mirtazapine is devoid of most side effects but has antihistamine side effects of drowsiness and weight gain. Its bioavailability is only fifty percent. The low bioavailability and side effects can be improved by altering the pharmokinetic profile of the drug by controlling the release of the drug. The slow release of the drug will reduce the harmful affect it has on the cells decreasing the side effects, as well as the loading of the drug in the nanocarrier will allow for a longer residence time in the body before it is removed by the gastrointestinal tract. In this research paper the pharmokinetic profile of Mirtazapine will be altered by surroundin.. Read More»
DOI:
10.4172/2169-0022.1000259
Journal of Material Sciences & Engineering received 3677 citations as per Google Scholar report